Urogen Pharma (URGN) – Research Analysts’ Weekly Ratings Updates

Several analysts have recently updated their ratings and price targets for Urogen Pharma (NASDAQ: URGN):

• 11/5/2026 – Urogen Pharma was given a new $60.00 price target by Oppenheimer.
• 11/5/2026 – Urogen Pharma had its “outperform” rating reaffirmed by UBS Group.
• 11/5/2026 – Urogen Pharma had its price target lowered by Guggenheim from $58.00 to $56.00. They now have a “buy” rating on the stock.
• 10/28/2026 – Urogen Pharma had its “outperform” rating reaffirmed by Oppenheimer.
• 10/19/2026 – Urogen Pharma had its “buy” rating reaffirmed by HC Wainwright. They now have a $75.00 price target on the stock.
• 10/15/2026 – Urogen Pharma had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 9/10/2026 – Urogen Pharma had its “buy” rating reaffirmed by Jefferies Financial Group. They now have a $56.00 price target on the stock.

Urogen Pharma Price Performance

Shares of Urogen Pharma stock traded down $0.98 on Friday, reaching $24.75. 1,736,911 shares of the company traded hands, compared to its average volume of 862,912. Urogen Pharma has a 52 week low of $16.50 and a 52 week high of $50.81. The company has a 50 day moving average of $39.20 and a 200 day moving average of $31.50. The firm has a market capitalization of $1.21 billion, a PE ratio of -18.75 and a beta of 1.68.

Urogen Pharma (NASDAQ:URGN) last posted its quarterly earnings data on Wednesday, November 4th. The company reported ($0.03) EPS for the quarter, missing the consensus estimate of $0.11 by ($0.14). The company had revenue of $89.00 million during the quarter, compared to analyst estimates of $89.92 million. As a group, analysts anticipate that Urogen Pharma will post -0.20 earnings per share for the current year.

Insider Activity

In related news, CFO Chris Degnan sold 2,202 shares of Urogen Pharma stock in a transaction dated Thursday, October 8th. The stock was sold at an average price of $36.69, for a total value of $80,791.38. Following the completion of the sale, the chief financial officer owned 4,561 shares of the company’s stock, valued at approximately $167,343.09. This trade represents a 32.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Mark Schoenberg sold 60,677 shares of the business’s stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $47.05, for a total value of $2,854,852.85. Following the completion of the sale, the insider owned 59,086 shares in the company, valued at $2,779,996.30. This represents a 50.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 65,269 shares of company stock valued at $3,037,646 in the last 90 days. Insiders own 4.80% of the company’s stock.

UroGen Pharma Ltd. (NASDAQ: URGN) is a biopharmaceutical company focused on developing and commercializing treatments for cancers of the urinary tract. The company’s therapies are designed to deliver medicines directly to the affected area, with the goal of improving drug exposure while limiting systemic side effects.

UroGen’s primary commercial product is Jelmyto, a mitomycin-based treatment approved in the United States for adults with low-grade upper tract urothelial cancer. Jelmyto uses UroGen’s proprietary RTGel technology, which forms a gel in the urinary tract and enables the sustained local release of mitomycin.

The company has also developed UGN-102, an investigational mitomycin-based reverse thermal gel intended for the treatment of low-grade, intermediate-risk non-muscle-invasive bladder cancer.